Takeda's Psoriasis Drug Application Granted Priority Review by FDA

The FDA has accepted Takeda's New Drug Application for zasocitinib (TAK-279), an investigational oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, under Priority Review. This designation accelerates the review process, supported by positive Phase 3 data showing effective skin clearance. A PDUFA target action date is set for Q1 2027, indicating a potential new treatment option for patients.